A carregar...
Dimethyl fumarate for relapsing MS
Dimethyl fumarate (DMF) is the latest oral therapy approved for relapsing-remitting multiple sclerosis (RRMS). In 2 placebo-controlled phase III trials, twice daily DMF demonstrated a 44%–53% reduction in annualized relapse rate and 71%–90% reduction in new MRI lesions. In one trial, DMF slowed the...
Na minha lista:
| Publicado no: | Neurol Clin Pract |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Academy of Neurology
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5798515/ https://ncbi.nlm.nih.gov/pubmed/29473631 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0b013e318296f10f |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|